[{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief therapeutics and NeuroRx File FDA IND for Aviptadil to Treat COVID-19-induced Respiratory Distress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Peptide","graph2":"Relief Therapeutics"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Relief Therapeutics Drug Aviptadil Enters FDA Trial at University of Miami, to Treat COVID-19-induced Respiratory Distress","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Peptide","graph2":"Relief Therapeutics"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Swisscanto","pharmaFlowCategory":"D","amount":"$15.3 million","upfrontCash":"Undisclosed","newsHeadline":"Memo Therapeutics AG Raises CHF 14 Million in a Series B Financing Round","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Memo Therapeutics"},{"orgOrder":0,"company":"Debiopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Phase II Research Against Covid-19 Launched IN France with Debiopharm\u2019s Antiviral Alisporivir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Debiopharm"},{"orgOrder":0,"company":"Kinarus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Hospitalized COVID-19 Patient Dosed with KIN001 in Phase 2 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Kinarus"},{"orgOrder":0,"company":"Rhizen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rhizen Pharmaceuticals AG Announces First Patient Dosed in a Phase 2 Study of RP7214 in Covid-19 Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Rhizen Pharmaceuticals"},{"orgOrder":0,"company":"GeNeuro","sponsor":"Swiss Federal Office of Public Health","pharmaFlowCategory":"D","amount":"$7.3 million","upfrontCash":"Undisclosed","newsHeadline":"Geneuro Receives CHF 6.7 Million (EUR 6.4 Million) in Funding From the Swiss Government for the Development of Temelimab Against Long-COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"GeNeuro"},{"orgOrder":0,"company":"Swiss PharmaCan","sponsor":"MGC Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Swiss Pharmacan's Supplement Authorized for Immediate Clinical Study to Confirm Effectiveness Against Long-COVID","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Swiss PharmaCan"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Wellcome","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Renews Commitment to Neglected Tropical Disease and Malaria Elimination, Investing USD 250 Million Over Five Years to Research and Develop New Treatments","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Kinarus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinarus Therapeutics to Hold Webinar on a New Approach to Treating COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Kinarus"},{"orgOrder":0,"company":"Kinarus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinarus Therapeutics Initiates KIN001 Phase II KINFAST Clinical Trial in COVID-19 Outpatients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Kinarus"},{"orgOrder":0,"company":"GeNeuro","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"GeNeuro"},{"orgOrder":0,"company":"Kinarus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinarus Therapeutics\u2019 KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Kinarus"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis and Medicines for Malaria Venture Announce Decision to Move to Phase 3 Study for Novel Ganaplacide\/lumefantrine-Sdf Combination in Adults and Children with Malaria","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Kinarus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Kinarus"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Vaxcyte","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"Lonza Group"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Under the expanded collaboration, Vaxcyte will utilise existing Lonza infrastructure to advance clinical development and commercialization of Vaxcyte’s PCV candidates, VAX-24, a 24-valent pneumococcal conjugate vaccine and VAX-31, in both the adult and pediatric populations.
Lead Product(s):
24-valent Pneumococcal Conjugate Vaccine
KIN001 is a patented combination of pamapimod, a highly selective investigational small molecule inhibitor of p38 mitogen-activated protein kinase (p38 MAPK), and pioglitazone, a marketed drug for the treatment of type 2 diabetes.
KIN001 is an orally available patented combination of pamapimod, a highly selective investigational small molecule inhibitor of p38 mitogen-activated protein kinase (p38 MAPK), and pioglitazone, a marketed drug for the treatment of type 2 diabetes.
KAF156 (Ganaplacide), belongs to a novel class of antimalarial molecules (imidazolopiperazines), has an effect on parasite internal protein secretory pathway. A key strength of the drug is its potential to both treat and prevent malaria, including resistant strains.
The trial will evaluate GNbAC1 (temelimab), the antiW-ENV antibody developed by GeNeuro, as a Disease Modifying Therapy in long-COVID patients suffering from concentration or fatigue problems.
KIN001 is an orally administered combination of two drugs that have demonstrated synergistic antiviral and anti-inflammatory activity, as well as ability to reduce tissue fibrosis.
KIN001 (pamapimod) is a proprietary novel combination of two active pharmaceutical ingredients that have demonstrated synergistic antiviral and anti-inflammatory activity, as well as ability to reduce tissue fibrosis in preclinical studies.
LXE408 is a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust. DNDi will lead Phase II and Phase III clinical development, with the first Phase II study scheduled to start in early 2021 in India.
The study includes 150 adult patients with a confirmed SARS-CoV-2 infection, at least 4 weeks of long-COVID symptoms, and a Post Covid Functional Score (PCFS) between one and four. ArtemiC Support is administered orally, in a dosage of 5 drops three times daily for 6 weeks.
Government funding will support a Phase 2 clinical trial with temelimab in patients suffering from Long- COVID with neurological and psychiatric symptoms.